Dr Reddy’s Laboratories ke liye FY27 ka growth momentum margin revival aur Semaglutide launch par depend karega. Company ne pichle saal US business pressures ki wajah se profit drop dekha tha, lekin ab gradual recovery ki umeed hai.
Dr Reddy’s ka FY27 growth plan: Semaglutide aur Abatacept launch se umeedein
Dr Reddy’s Laboratories anticipate kar rahi hai ki is fiscal year mein dheere-dheere recovery hogi. Company ko India, Europe, aur emerging markets mein healthy growth mil rahi hai. Naye launches jaise Semaglutide aur Abatacept se future expansion ki umeed hai.
Margin revival kaise hogi: Product mix aur cost control se
Margins improve hone ki umeed hai kyunki company better product mix aur cost controls par focus kar rahi hai. US business ke pressures ke baad ab company apne operations ko stable karne ki koshish kar rahi hai.
Hamaari Baat: Dr Reddy’s ke liye FY27 kyun important hai
Seedha baat karein toh Dr Reddy’s ke liye FY27 ek turnaround year ho sakta hai. US business mein jo dikkat aayi thi, usse recover karna time lagega. Lekin India, Europe, aur emerging markets mein growth positive signal hai. Semaglutide aur Abatacept jaisi launches se company ko naye markets mein entry mil sakti hai. Margin revival ke liye product mix aur cost control par focus sahi strategy hai. Investors ko FY27 ke numbers par nazar rakhni chahiye.
Sources & References
- Dr Reddy’s Laboratories Growth Outlook — Original Story
